Alfonso Sebastian Lopez, MD, Mayo Clinic, Jacksonville, FL, explores the latest developments in the treatment of antibody-mediated autoimmune encephalitis. There are ongoing efforts to identify the most effective treatments for patients, including clinical trials. Specifically, the ExTINGUISH (NCT04372615) is investigating the efficacy of inebilizumab in patients with anti-NMDA receptor encephalitis. Other trials are focusing on different types of antibody-driven encephalitis. Dr Lopez expresses excitement at the prospect of having strong data from these trials to guide treatment decisions, as the current approach is largely based on expert opinions. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть